Poseida Therapeutics Inc (PSTX)
9.49
+0.01
(+0.11%)
USD |
NASDAQ |
Dec 24, 16:00
Poseida Therapeutics Research and Development Expense (Quarterly): 41.91M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Galectin Therapeutics Inc | 7.595M |
| Revance Therapeutics Inc | 11.38M |
| Sage Therapeutics Inc | 54.58M |
| Alector Inc | 48.00M |
| Phathom Pharmaceuticals Inc | 8.693M |